文献速递淋巴瘤白血病

奥妥珠单抗、阿可替尼和维奈克拉联合或不联合苯达莫司汀减瘤治疗复发或难治性慢性淋巴细胞白血病(CLL2-BAAG):多中心、开放标签、2期试验

Obinutuzumab, acalabrutinib, and venetoclax, after an optional debulking with bendamustine in relapsed or refractory chronic lymphocytic leukaemia (CLL2-BAAG): a multicentre, open-label, phase 2 trial.
PubMed 文献 · Lancet Haematol · 2022-08-18

这项多中心、开放标签、研究者发起的2期试验评估了奥妥珠单抗、阿可替尼和维奈克拉三联方案(可选苯达莫司汀减瘤)治疗复发或难治性慢性淋巴细胞白血病。45例可评估患者中,34例(76%;95%CI 61-87,p=0.26)在外周血达到uMRD,未达到预设活性阈值。常见3-4级不良事件为血小板减少和中性粒细胞减少(各12例[27%])。

要点

  • 45例可评估患者中34例(76%)达到外周血uMRD,未达到预设活性阈值。
  • 中位观察13.8个月(IQR 10.4-18.4)期间无进展、无死亡,发生2例(4%)Richter转化。
  • 最常见3-4级不良事件为血小板减少和中性粒细胞减少(各12例[27%])。

核心结论

  • 76%的患者在外周血达到uMRD,但该试验未达到预设活性阈值。
  • 奥妥珠单抗、阿可替尼和维奈克拉三联方案(可选苯达莫司汀减瘤)需在更大规模试验中进一步评估,以明确其相对于BTK或BCL2抑制剂联合奥妥珠单抗双药治疗或两种口服靶向药物联合的价值。
  • 在这些试验显示明确获益之前,不建议在常规实践中使用该三联方案。

研究设计与样本

  • 多中心、开放标签、研究者发起的2期研究,评估序贯治疗:高肿瘤负荷患者先接受2个周期苯达莫司汀减瘤(70 mg/m2静脉注射,第1-2天,28天后重复),随后诱导和维持治疗。
  • 诱导和维持方案:奥妥珠单抗(首个诱导周期第1-2、8、15天静脉注射1000 mg,诱导周期2-6每4周一次,维持阶段每12周一次)、阿可替尼(从诱导周期2第1天起100 mg口服每日两次持续给药)、维奈克拉(从诱导周期3开始,20 mg/日,每周剂量递增,5周内增至目标剂量400 mg/日)。
  • 入组标准:年龄≥18岁,ECOG体能评分0-2,根据2018年国际慢性淋巴细胞白血病工作组标准需要治疗的复发或难治性慢性淋巴细胞白血病。
  • 主要终点:诱导治疗结束时外周血uMRD(<10-4),在末次诱导周期开始后12周最终再分期时集中评估;按方案,所有接受超过2个诱导周期的患者纳入分析。
  • 2019年1月14日至2020年6月25日入组45例可评估患者;13例(29%)女性,32例(71%)男性,21例(47%)已接受过靶向药物,14例(32%)有del(17)(p13.1)或TP53突变;未收集种族数据。

主要发现

  • 数据截止(2021年2月25日)时,所有患者已完成诱导治疗;34例(76%;95%CI 61-87,p=0.26)在三联治疗6个月后外周血达到uMRD。
  • 截至数据截止,32例(71%)患者开始维持治疗,9例(28%)达到uMRD后能够停止治疗。
  • 中位观察时间13.8个月(IQR 10.4-18.4)期间,发生2例(4%)Richter转化,未观察到进展和死亡。
  • 整个治疗期间最常见的3-4级不良事件为血小板减少和中性粒细胞减少(各12/45例[27%])、肿瘤溶解综合征和感染(各5/45例[11%],仅3级不良事件)、输注相关反应(4/45例[9%])和贫血(4/45例[9%])。

关键数值与推荐

  • 主要终点uMRD定义为外周血<10-4,于末次诱导周期开始后12周最终再分期时集中评估。
  • 苯达莫司汀减瘤剂量:70 mg/m2静脉注射,第1-2天,28天后重复,共2个周期。
  • 奥妥珠单抗剂量:首个诱导周期第1-2、8、15天静脉注射1000 mg,诱导周期2-6每4周一次,维持阶段每12周一次。
  • 阿可替尼剂量:从诱导周期2第1天起100 mg口服每日两次持续给药。
  • 维奈克拉剂量:从诱导周期3开始20 mg/日,每周剂量递增,5周内增至目标剂量400 mg/日。

临床怎么用

  • 作者认为,在这些试验显示明确获益之前,不建议在常规实践中使用该三联方案。

局限性

  • 该试验未达到预设活性阈值,三联方案需在更大规模试验中进一步评估。
  • 需进一步评估以明确其相对于BTK或BCL2抑制剂联合奥妥珠单抗双药治疗或两种口服靶向药物联合的价值。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Although BTK inhibitors provide long-term disease-control in patients with chronic lymphocytic leukaemia, they need to be combined with BCL2 inhibitors or antibodies to achieve deep responses with undetectable minimal residual disease (uMRD), which allows for time-limited treatment. This trial aims to evaluate the triple combination of obinutuzumab, acalabrutinib, and venetoclax after an optional debulking with bendamustine. METHODS: This multicentre, open-label, investigator-initiated, phase 2 study evaluates a sequential treatment consisting of a debulking with two cycles of bendamustine for patients with a higher tumour load (70 mg/m2 intravenously on days 1 and 2, repeated after 28 days), followed by an induction and a maintenance with obinutuzumab (1000 mg intravenously on days 1-2, 8, and 15 of the first induction cycle, every 4 weeks in induction cycles 2-6 and every 12 weeks in the maintenance phase), acalabrutinib (100 mg orally twice daily continuously from induction cycle 2 day 1 onwards) and venetoclax (starting in induction cycle 3 with 20 mg per day with a weekly dose ramp-up over 5 weeks to the target dose of 400 mg per day). Eligible patients were aged 18 years or older with an ECOG performance score 0-2 and had relapsed or refractory chronic lymphocytic leukaemia requiring treatment according to the 2018 International Workshop on Chronic Lymphocytic Leukemia criteria. The primary endpoint was uMRD (<10-4) in peripheral blood at the end of induction treatment assessed centrally at the final restaging, 12 weeks after the start of the last induction cycle. As per protocol, all patients with more than two induction cycles were included in the analyses. This study is registered with ClinicalTrials.gov, number NCT03787264, and is ongoing. FINDINGS: Between Jan 14, 2019, and June 25, 2020, 45 evaluable patients with relapsed or refractory chronic lymphocytic leukaemia were enrolled; 13 (29%) were female, 32 (71%) were male, 21 (47%) had already received a targeted agent, and 14 (32%) had del(17)(p13.1) or TP53 mutation. Ethnicity-race data was not collected. At data cutoff (Feb 25, 2021), all patients had completed the induction treatment. 34 patients (76%; 95% CI 61-87, p=0·26) had uMRD in peripheral blood after 6 months of triple therapy. Until data cutoff, 32 (71%) patients started maintenance and nine (28%) were able to stop with uMRD. After a median observation time of 13·8 months (IQR 10·4-18·4), there were two (4%) Richter transformations, but no progressions and no deaths observed. The most common adverse events of grade 3 and 4 during the entire treatment were thrombocytopenia and neutropenia (12 [27%] of 45 patients each), tumour lysis syndrome and infections (five [11%] of 45 patients each, grade 3 adverse events only), infusion-associated reactions (four [9%] of 45 patients) and anaemia (four [9%] of 45 patients). INTERPRETATION: With 76% of patients achieving uMRD in peripheral blood, this trial did not reach the prespecified activity threshold. Triple therapy with obinutuzumab, acalabrutinib, and venetoclax after an optional debulking with bendamustine regimen requires further evaluation in larger trials to define its value compared with double treatment with a BTK or BCL2 inhibitor combined with obinutuzumab or a combination of the two oral targeted drugs. Until these trials show a clear benefit, the use of the triple combination in routine practice cannot be recommended. FUNDING: Acerta, AstraZeneca, F Hoffmann-La Roche, and AbbVie.

来源:Lancet Haematol,查看原文。版权归原作者所有。

引用

  1. Cramer P, Fürstenau M, Robrecht S, et al. Obinutuzumab, acalabrutinib, and venetoclax, after an optional debulking with bendamustine in relapsed or refractory chronic lymphocytic leukaemia (CLL2-BAAG): a multicentre, open-label, phase 2 trial. Lancet Haematol. 2022. PMID: 35988545. doi:10.1016/S2352-3026(22)00211-3

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。